As of September 30, 2026, Dianthus Therapeutics, Inc. carries a market capitalization of 4.33B, placing it among publicly traded companies globally. Its enterprise value stands at 3.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.33B |
| Enterprise Value | 3.60B |
Dianthus Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 16, 2027.
| Earnings Date | 3/16/2027 |
As of September 30, 2026, Dianthus Therapeutics, Inc. has 56.30M shares outstanding.
| Shares Outstanding | 56.30M |
These figures are as of September 30, 2026. The price-to-sales ratio is 1,656.61, and the price-to-book ratio stands at 3.96.
| PS Ratio | 1,656.61 |
| PB Ratio | 3.96 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | -25.71 |
| P/OCF Ratio | -25.71 |
These figures are as of September 30, 2026. The EV/Sales ratio of 1,499.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.60B versus a market cap of 4.33B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1,499.79 |
As of September 30, 2026, Dianthus Therapeutics, Inc. maintains a current ratio of 30.02, meaning it holds 30.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 30.02 |
| Quick Ratio | 29.40 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | -0.01 |
Over the twelve months ended September 30, 2026, Dianthus Therapeutics, Inc. posted a negative return on equity (ROE) of -22.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.81, reflecting losses generated across the asset base. The company generates approximately 26,066.21 in revenue per employee across its workforce of 92.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -22.61 |
| Return on Assets (ROA) | -21.81 |
| Revenue Per Employee | 26,066.21 |
| Employee Count | 92.00 |
As of the close on November 17, 2026, Dianthus Therapeutics, Inc.'s stock has gained approximately 123.31% over the past 52 weeks. The 50-day moving average sits at 76.72, while the 200-day moving average is 75.14.
| 52-Week Price Change | 123.31% |
| 50-Day Moving Average | 76.72 |
| 200-Day Moving Average | 75.14 |
Over the twelve months ended September 30, 2026, Dianthus Therapeutics, Inc. generated 2.40M in revenue and converted that into -178.33M in net income, yielding earnings per share of -3.46. EBITDA reached -207.90M, while operating income came in at -208.25M.
| Revenue | 2.40M |
| Operating Income | -208.25M |
| Pretax Income | -178.33M |
| Net Income | -178.33M |
| EBITDA | -207.90M |
| EBIT | -208.25M |
| Earnings Per Share (EPS) | -3.46 |
As of September 30, 2026, Dianthus Therapeutics, Inc. holds 739.18M in cash and equivalents against 1.07M in total debt, resulting in a net debt position of -49.13M. Total book value stands at 1.10B, with working capital of 730.12M providing operational flexibility.
| Cash & Cash Equivalents | 739.18M |
| Total Debt | 1.07M |
| Net Debt | -49.13M |
| Equity (Book Value) | 1.10B |
| Book Value Per Share | 19.46 |
| Working Capital | 730.12M |
Dianthus Therapeutics, Inc. produced -154.54M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | -154.54M |
| Free Cash Flow | -154.54M |
| FCF Per Share | -3.00 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -8,683.89 and net profit margin of -7,436.50 provide insight into operational efficiency.
| Operating Margin | -8,683.89 |
| Pretax Margin | -7,436.50 |
| Profit Margin | -7,436.50 |
| EBITDA Margin | -8,669.57 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -3.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.55, meaning Dianthus Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -17.55 |
| FCF Yield | -3.89 |
Dianthus Therapeutics, Inc.'s most recent stock split took place on September 12, 2023 with a 16:1 split ratio.
| Last Split Date | 9/12/2023 |
| Split Ratio | 16:1 |
As of September 30, 2026, Dianthus Therapeutics, Inc. has an Altman Z-Score of 84.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 84.30 |